Although mpMRI can improve targeting of clinically significant prostate cancer, its performance depends in part on obtaining ...
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...
Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence ...
A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active surveillance. Use of the test to determine the need for repeat "monitoring" biopsies ...
Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...
SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) was a Phase II multi-centre, single arm, non-randomised, open-label copper-64 labelled SAR-Bombesin PET imaging trial of ...
Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results